The TGFβ pathway is exquisitely involved in T-cell autoimmunity and has been linked with HT for some time, as treatment of cancer patients with IL-2, a downstream target of the pathway, resulted in increased incidence of HT (Weijl et al., 1993). This evidence concerns the gene TGFB1 and hematocrit.